Silence Therapeutics priced an upsized public offering to raise about $175 million, targeting short interfering RNA (siRNA) programs including divesiran. The financing arrived after the company reported a “best-case” outcome in a Phase 2 study for divesiran in a rare leukemia indication. The share sale increases the originally proposed capital raise of roughly $150 million, with about 12.96 million American depositary shares priced at $13.50 each. Net proceeds are expected to support continued development across the company’s RNA pipeline and broader operational needs. For the biotech market, the deal underscores how quickly capital markets have responded to Phase 2 data—especially for platform-driven companies in the siRNA space where investors often focus on proof-of-concept signals and differentiation in dosing and durability.